SCHEMBL3403801

SCHEMBL3403801

CCn1c(-c2cccc3ccccc23)nc(F)c1[Si](C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
HTR2C P28335 8/20 0.38
HTR2A P28223 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 3/20 0.36
HSD17B10 Q99714 2/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
ENPP3 O14638 1/20 0.36
ENPP1 P22413 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
DHFR P00374 1/20 0.35
ALOX15 P16050 2/20 0.34
TLR8 Q9NR97 1/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
ALOX12 P18054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3399706 0.75 KDM4E (0.41) KDM4EHTR2CHTR2ACYP1A2CYP3A4
SCHEMBL3404825 0.74 PTGER4 (0.43) KDM4EHTR2CHTR2ACYP1A2CYP3A4
SCHEMBL3399414 0.70 KDM4E (0.41) KDM4EHTR2CHTR2AALDH1A1HSD17B10
SCHEMBL3403551 0.67 KDM4E (0.44) KDM4EHTR2CALDH1A1HPGD
SCHEMBL14545925 0.67 ALDH1A1 (0.44) KDM4EHTR2CCYP1A2CYP3A4CYP2C19
SCHEMBL3400011 0.66 ALDH1A1 (0.50) KDM4EALDH1A1HSD17B10LMNAHPGD
SCHEMBL3405737 0.66 MAPK1 (0.59) KDM4EHTR2CCYP1A2ALDH1A1HSD17B10
SCHEMBL3402974 0.65 KDM4E (0.48) KDM4EHTR2CCYP1A2CYP3A4CYP2C19
SCHEMBL5549123 0.62 MAPK13 (0.44) KDM4EHTR2CHTR2ACYP1A2CYP3A4
Alcohol SCHEMBL7737056 0.62 PPARG (0.47) CYP1A2CYP2C19ALDH1A1HSD17B10ENPP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2008063134-A1 METHOD OF PRODUCING A PATTERN OF DISCRIMINATIVE WETTABILITY AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2008-05-29 WO disclosed
EP-1848428-A2 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-10-31 EP disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed
WO-2006089076-A2 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 KDM4E 3449/4885HTR2C 416/4885HTR2A 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.